Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma

Chang Gung Medical Journal

Volumn 34, Issue 5, 2011, Pages 478-486

  Su, Po Jung ^a   Chen, Jen Shi ^a   Liaw, Chuang Chi ^a   Chang, Hsien Kun ^a   Wang, Hung Ming ^a   Yang, Tsia Sheng ^a   Lin, Yung Chang ^a   Liau, Chi Ting ^a   Yang, Hsin Yi ^a   Yeh, Kun Yun ^a   Ho, Ming Mo ^a   Chang, Nai Jun ^a   Wang, Cheng Hsu ^a   Chang, John Wen Chen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Carmustine; Cisplatin; Dacarbazine; Interleukin 2; Malignant melanoma; Tamoxifen

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; TAMOXIFEN;

ADULT; AGED; ANEMIA; ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; FEMALE; FEVER; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER DISEASE; LOW DRUG DOSE; MALAISE; MALE; MELANOMA; MENTAL DISEASE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SKIN INDURATION; SKIN PRURITUS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CISPLATIN; DACARBAZINE; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; TAMOXIFEN;

EID: 80055094589     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984;68:1403-5.
2. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazinebased chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21-34.
3. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2083-90.
4. Johnston SR, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G, Riches PG, Gore ME. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998;77:1280-6.
5. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
6. Chiarion Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, Favaretto AG, Cetto GL, Monfardini S. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001;11:189-96.
7. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002;29:413-26.
8. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
9. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-9.
10. Naglieri E, Procacci A, Galetta D, Abbate I, Dell'Erba L, Colucci G. Cisplatin, interleukin-2, interferon-alpha and tamoxifen in metastatic melanoma. A phase II study. J Chemother 1999;11:150-5.
11. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80.
12. Fabbri M, Ridolfi R, Maltoni R, Ridolfi L, Riccobon A, Flamini E, De Paola F, Verdecchia GM, Amadori D. Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma. Tumori 2000;86:46-52.
13. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
14. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
15. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995;18:272-8.
16. MacFarlane MP, Yang JC, Guleria AS, White RL Jr, Seipp CA, Einhorn JH, White DE, Rosenberg SA. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer 1995;75:1030-7.
17. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82.
18. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003;95:741-9.
19. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:5748-54.
20. Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C. Phase II trial of subcutaneous interleukin-2, subcutaneous interferonalpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Cancer Biother Radiopharm 2000;15:487-94.
21. Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:1600-7.
22. Quan WD Jr, Quan FM. Outpatient experience with moderate dose bolus interleukin-2 in metastatic malignant melanoma and kidney cancer. J Immunother 2003;26:286-90.
23. Yang TS, Ng KT, Wang HM, Kiu MC, Wang CH, Lai GM. Combination chemotherapy with BCNU cisplatin DTIC plus tamoxifen for metastatic malignant melanoma. J Chin Oncol Soc 1993;9:18-24.
24. Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC, Kuo TT, Yang CH. Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res 2004;14:537-41.
25. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-59.
26. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185-93.
27. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007;25:5426-34.
28. Hess V, Herrmann R, Veelken H, Schwabe M. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting. Oncology 2007;73:33-40.
29. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and lowdose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32.
30. Weinreich DM, Rosenberg SA. Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or lowdose interleukin-2. J Immunother 2002;25:185-7.
31. Carlson RH. Donald Morton: 'Resect Melanoma Metastases before They Metastasize'. Oncology Times 2005;27:32-33.
32. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22:2101-7.
33. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-8.
34. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455-64.
35. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30.
36. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006;12:2366s-70s.